Cue Biopharma (NASDAQ:CUE – Get Free Report) and CalciMedica (NASDAQ:CALC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Institutional and Insider Ownership
35.0% of Cue Biopharma shares are owned by institutional investors. 12.3% of Cue Biopharma shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Cue Biopharma and CalciMedica”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $9.29 million | 6.10 | -$40.67 million | ($0.56) | -1.32 |
| CalciMedica | N/A | N/A | -$13.70 million | ($1.60) | -1.94 |
CalciMedica has lower revenue, but higher earnings than Cue Biopharma. CalciMedica is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cue Biopharma and CalciMedica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -469.35% | -230.13% | -111.16% |
| CalciMedica | N/A | -206.51% | -103.81% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Cue Biopharma and CalciMedica, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| CalciMedica | 1 | 0 | 1 | 0 | 2.00 |
CalciMedica has a consensus price target of $16.00, indicating a potential upside of 414.47%. Given CalciMedica’s stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Cue Biopharma.
Risk and Volatility
Cue Biopharma has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
Summary
CalciMedica beats Cue Biopharma on 8 of the 13 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
About CalciMedica
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
